JPWO2022049526A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022049526A5 JPWO2022049526A5 JP2023514117A JP2023514117A JPWO2022049526A5 JP WO2022049526 A5 JPWO2022049526 A5 JP WO2022049526A5 JP 2023514117 A JP2023514117 A JP 2023514117A JP 2023514117 A JP2023514117 A JP 2023514117A JP WO2022049526 A5 JPWO2022049526 A5 JP WO2022049526A5
- Authority
- JP
- Japan
- Prior art keywords
- antagonist
- heavy chain
- light chain
- olinvasimab
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063073512P | 2020-09-02 | 2020-09-02 | |
| US63/073,512 | 2020-09-02 | ||
| US202063122321P | 2020-12-07 | 2020-12-07 | |
| US63/122,321 | 2020-12-07 | ||
| PCT/IB2021/058043 WO2022049526A1 (en) | 2020-09-02 | 2021-09-02 | Combination therapy of a pd-1 antagonist and an antagonist for vegfr-2 for treating patients with cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023540490A JP2023540490A (ja) | 2023-09-25 |
| JP2023540490A5 JP2023540490A5 (https=) | 2024-08-21 |
| JPWO2022049526A5 true JPWO2022049526A5 (https=) | 2024-08-21 |
Family
ID=77914405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023514117A Pending JP2023540490A (ja) | 2020-09-02 | 2021-09-02 | がん患者を治療するためのｐｄ－１拮抗薬及びｖｅｇｆｒ－２拮抗薬の併用療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230265196A1 (https=) |
| EP (1) | EP4208482A1 (https=) |
| JP (1) | JP2023540490A (https=) |
| KR (1) | KR20230087451A (https=) |
| AU (1) | AU2021337223A1 (https=) |
| CA (1) | CA3189987A1 (https=) |
| MX (1) | MX2023002570A (https=) |
| WO (1) | WO2022049526A1 (https=) |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JP2002531466A (ja) | 1998-12-01 | 2002-09-24 | プロテイン デザイン ラブス， インコーポレイテッド | γ−インターフェロンに対するヒト化抗体 |
| SI1916001T1 (sl) | 2002-03-04 | 2011-10-28 | Imclone Llc | Äśloveĺ ka protitelesa specifiäśna za kdr in njihova uporaba |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| US7563869B2 (en) | 2003-01-23 | 2009-07-21 | Ono Pharmaceutical Co., Ltd. | Substance specific to human PD-1 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| CN102203132A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂的组合物和使用方法 |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| ES2676205T3 (es) | 2011-03-31 | 2018-07-17 | Merck Sharp & Dohme Corp. | Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| JP6742903B2 (ja) | 2013-05-02 | 2020-08-19 | アナプティスバイオ インコーポレイティッド | プログラム死−１（ｐｄ−１）に対する抗体 |
| US9676853B2 (en) | 2013-05-31 | 2017-06-13 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-1 |
| EA034666B1 (ru) | 2013-09-13 | 2020-03-04 | Бейджин Свитзерланд Гмбх | Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| SG10201900002QA (en) | 2014-01-24 | 2019-02-27 | Dana Farber Cancer Institue Inc | Antibody molecules to pd-1 and uses thereof |
| US20190183972A1 (en) * | 2016-06-03 | 2019-06-20 | Imclone Llc | Combination of ramucirumab and pembrolizumab for the treatment of certain cancers |
-
2021
- 2021-09-02 KR KR1020237010758A patent/KR20230087451A/ko active Pending
- 2021-09-02 CA CA3189987A patent/CA3189987A1/en active Pending
- 2021-09-02 JP JP2023514117A patent/JP2023540490A/ja active Pending
- 2021-09-02 AU AU2021337223A patent/AU2021337223A1/en active Pending
- 2021-09-02 US US18/043,602 patent/US20230265196A1/en active Pending
- 2021-09-02 EP EP21777846.3A patent/EP4208482A1/en active Pending
- 2021-09-02 WO PCT/IB2021/058043 patent/WO2022049526A1/en not_active Ceased
- 2021-09-02 MX MX2023002570A patent/MX2023002570A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025016606A5 (https=) | ||
| JP2019515008A5 (https=) | ||
| JP2020503260A5 (https=) | ||
| JP2015534579A5 (https=) | ||
| JP2011507932A5 (https=) | ||
| JP2017501167A5 (https=) | ||
| JP2014533279A5 (https=) | ||
| KR20200020902A (ko) | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 | |
| JP2009518441A5 (https=) | ||
| WO2018223923A1 (zh) | Pd-1抗体与vegf配体或vegf受体抑制剂联合在制备治疗肿瘤的药物中的用途 | |
| JP2020515577A5 (https=) | ||
| AU2016260895A1 (en) | Treatment for multiple myeloma (MM) | |
| JP2024016209A5 (https=) | ||
| JPWO2019160755A5 (https=) | ||
| TW202207976A (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| CN111166878B (zh) | 靶向肿瘤抗原的抗体与iNKT细胞的组合的制备方法与用途 | |
| JPWO2021224499A5 (https=) | ||
| JPWO2020096915A5 (https=) | ||
| CN115698076A (zh) | 用于治疗肿瘤的药物 | |
| JPWO2022049526A5 (https=) | ||
| JPWO2020223702A5 (https=) | ||
| JP2022125157A (ja) | 抗－ｖｅｇｆｒ－２抗体 | |
| JPWO2021087016A5 (https=) | ||
| JPWO2023177772A5 (https=) | ||
| JP2021524446A5 (https=) |